RSS
12 Nov 2020

KAHR Announces First Patient Dosed in Phase 1/2 Clinical Trial of DSP107, Bi-Functional CD47x41BB Candidate for the Treatment of Solid Tumors

Author: admintech | Filed under: Press Release

JERUSALEM, Nov. 12, 2020 /PRNewswire/ — KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced dosing of the first patient in its Phase 1/2 clinical trial (NCT04440735) assessing its lead product, DSP107, a bi-functional…

This entry was posted on Thursday, November 12th, 2020 at 6:53 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

«

»